Study Assessing Safety and Efficacy of Buntanetap in Participants With Early Alzheimer's Disease

Clinical Trial Title A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease
National Clinical Trial Number: NCT06709014

Clinical Trial Protocol Description:

This study will test if an investigational drug called buntanetap is safe and helpful to people with memory and thinking problems associated with early Alzheimer鈥檚 disease (AD).

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are between 55 and 85 years of age.
  • Have a diagnosis of mild cognitive impairment (MCI) or early Alzheimer's disease (AD).
  • Have a study partner (such as a spouse, family member, or close friend) willing and able to attend study visits with you and to answer questions about you to study staff.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Raj C. Shah, MD

Contact Information

Leann Donovan
Clinical Trial Location
海角原创

Contact Information

Location

海角原创

1620 W Harrison St
Chicago, IL 60612

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more